Literature DB >> 21172414

Why do patients with psychosis use cannabis and are they ready to change their use?

Anna Kolliakou1, Candice Joseph, Khalida Ismail, Zerrin Atakan, Robin M Murray.   

Abstract

Numerous studies have shown that patients with psychosis are more likely to use illicit drugs than the general population, with cannabis being the most popular. There exists overwhelming evidence that cannabis use can contribute to the onset of schizophrenia and poor outcome in patients with established psychosis. Therefore, understanding why patients use cannabis and whether they are motivated to change their habits is important. The evidence is that patients with psychosis use cannabis for the same reasons the general population does, to 'get high', relax and have fun. There is little support for the 'self-medication' hypothesis, while the literature points more towards an 'alleviation of dysphoria' model. There is a lack of research reporting on whether psychotic patients are ready to change their use of cannabis, which has obvious implications for identifying which treatment strategies are likely to be effective.
Copyright © 2010 ISDN. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21172414     DOI: 10.1016/j.ijdevneu.2010.11.006

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  9 in total

1.  Perspective: Be clear about the real risks.

Authors:  Matthew Hill
Journal:  Nature       Date:  2015-09-24       Impact factor: 49.962

2.  Cannabis: debated schizophrenia link.

Authors:  Matthew Large; Marta Di Forti; Robin Murray
Journal:  Nature       Date:  2015-11-19       Impact factor: 49.962

3.  Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management.

Authors:  Jonathan R Stevens; Jefferson B Prince; Laura M Prager; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2014-03-13

Review 4.  Functional diversity on synaptic plasticity mediated by endocannabinoids.

Authors:  Roger Cachope
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

5.  A comparative study of socio-demographic and substance use correlates in early-onset psychosis.

Authors:  Saeeda Paruk; Khatija Jhazbhay; Keshika Singh; Benn Sartorius; Jonathan K Burns
Journal:  Early Interv Psychiatry       Date:  2016-04-01       Impact factor: 2.732

6.  Developing a theoretical framework for persistent cannabis use among young adults with first episode psychosis.

Authors:  Leslie Marino; Samantha E Jankowski; Rick Kent; Michael L Birnbaum; Ilana Nossel; Jean-Marie Alves-Bradford; Lisa Dixon
Journal:  Early Interv Psychiatry       Date:  2021-05-16       Impact factor: 2.732

7.  Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.

Authors:  Felipe V Gomes; Francisco S Guimarães; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-13       Impact factor: 5.176

8.  Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.

Authors:  Alexandre Seillier; Alex A Martinez; Andrea Giuffrida
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

9.  Adverse effects of heavy cannabis use: even plants can harm the brain.

Authors:  Lucia Sideli; Giulia Trotta; Edoardo Spinazzola; Caterina La Cascia; Marta Di Forti
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.